If you are interested in ipilimumab, then the following is from the NICE website:
“A skin cancer treatment should only be used by the NHS for patients in clinical trials to ensure that evidence for its clinical effectiveness continues to be collected, says the National Institute for Health and Care Excellence (NICE).
manufactured by Bristol-Myers Squibb Pharmaceuticals Limited) is used only in the context of research as a first-line treatment for patients with advanced malignant melanoma which is either unresectable (when the full tumour cannot be removed) or metastatic (the cancer has spread to other parts of the body). The draft guidance states that people currently receiving ipilimumab as part of their NHS care should continue with the treatment until they and their doctor consider it appropriate to stop.”